Diagnosis and treatment of pulmonary hypertension in infancy

Early Hum Dev. 2013 Nov;89(11):865-74. doi: 10.1016/j.earlhumdev.2013.09.012. Epub 2013 Sep 29.

Abstract

Normal pulmonary vascular development in infancy requires maintenance of low pulmonary vascular resistance after birth, and is necessary for normal lung function and growth. The developing lung is subject to multiple genetic, pathological and/or environmental influences that can adversely affect lung adaptation, development, and growth, leading to pulmonary hypertension. New classifications of pulmonary hypertension are beginning to account for these diverse phenotypes, and or pulmonary hypertension in infants due to PPHN, congenital diaphragmatic hernia, and bronchopulmonary dysplasia (BPD). The most effective pharmacotherapeutic strategies for infants with PPHN are directed at selective reduction of PVR, and take advantage of a rapidly advancing understanding of the altered signaling pathways in the remodeled vasculature.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Bosentan
  • Bronchopulmonary Dysplasia / diagnosis
  • Bronchopulmonary Dysplasia / physiopathology*
  • Bronchopulmonary Dysplasia / therapy
  • Hernia, Diaphragmatic / diagnosis
  • Hernia, Diaphragmatic / physiopathology*
  • Hernia, Diaphragmatic / therapy
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / physiopathology*
  • Hypertension, Pulmonary / therapy
  • Infant, Newborn
  • Milrinone / therapeutic use
  • Nitric Oxide / therapeutic use
  • Piperazines / therapeutic use
  • Prostaglandins / therapeutic use
  • Purines / therapeutic use
  • Signal Transduction / physiology*
  • Sildenafil Citrate
  • Sulfonamides / therapeutic use
  • Sulfones / therapeutic use
  • Vascular Resistance / physiology*

Substances

  • Piperazines
  • Prostaglandins
  • Purines
  • Sulfonamides
  • Sulfones
  • Nitric Oxide
  • Sildenafil Citrate
  • Milrinone
  • Bosentan